• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015

tetano

Editor, Senior Moderator
Antiviral Res. 2016 Jun 2. pii: S0166-3542(16)30216-9. doi: 10.1016/j.antiviral.2016.06.001. [Epub ahead of print]
[h=1]Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015.[/h] Hurt AC[SUP]1[/SUP], Besselaar TG[SUP]2[/SUP], Daniels RS[SUP]3[/SUP], Ermetal B[SUP]3[/SUP], Fry A[SUP]4[/SUP], Gubareva L[SUP]4[/SUP], Huang W[SUP]5[/SUP], Lackenby A[SUP]6[/SUP], Lee RT[SUP]7[/SUP], Lo J[SUP]8[/SUP], Maurer-Stroh S[SUP]9[/SUP], Nguyen HT[SUP]4[/SUP], Pereyaslov D[SUP]10[/SUP], Rebelo-de-Andrade H[SUP]11[/SUP], Siqueira MM[SUP]12[/SUP], Takashita E[SUP]13[/SUP], Tashiro M[SUP]13[/SUP], Tilmanis D[SUP]14[/SUP], Wang D[SUP]5[/SUP], Zhang W[SUP]2[/SUP], Meijer A[SUP]15[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] The World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza (WHO CCs) tested 13,312 viruses collected by WHO recognized National Influenza Centres between May 2014 and May 2015 to determine 50% inhibitory concentration (IC[SUB]50[/SUB]) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. Ninety-four per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 0.5% (n = 68) of viruses showed either highly reduced inhibition (HRI) or reduced inhibition (RI) (n = 56) against at least one of the four NAIs. Of the twelve viruses with HRI, six were A(H1N1)pdm09 viruses, three were A(H3N2) viruses and three were B/Yamagata-lineage viruses. The overall frequency of viruses with RI or HRI by the NAIs was lower than that observed in 2013-14 (1.9%), but similar to the 2012-13 period (0.6%). Based on the current analysis, the NAIs remain an appropriate choice for the treatment and prophylaxis of influenza virus infections.
Copyright ? 2016. Published by Elsevier B.V.


[h=4]KEYWORDS:[/h] Antiviral resistance; Global analysis; Influenza virus; Neuraminidase inhibitors; Oseltamivir; Reduced susceptibility

PMID: 27265623 [PubMed - as supplied by publisher] Free full text
 
Back
Top Bottom